Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al
ContributorsWahl, Denis; Lecompte, Thomas Pierre; Bounameaux, Henri
Published inArthritis and rheumatism, vol. 58, no. 2, p. 635-636
Publication date2008
Keywords
- Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
- Antibodies, Antiphospholipid/blood
- Antiphospholipid Syndrome/drug therapy/epidemiology/immunology
- Aspirin/therapeutic use
- Humans
- Risk Factors
- Thrombosis/epidemiology/immunology/prevention & control
NoteWith author reply (p. 636) - Comment on: Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, Sammaritano L, Unalp-Arida A, Vilela V, Yazici Y, Lockshin MD. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 Jul;56(7):2382-91.
Affiliation entities
Citation (ISO format)
WAHL, Denis, LECOMPTE, Thomas Pierre, BOUNAMEAUX, Henri. Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al. In: Arthritis and rheumatism, 2008, vol. 58, n° 2, p. 635–636. doi: 10.1002/art.23160
Main files (1)
Article (Accepted version)
Identifiers
- PID : unige:1837
- DOI : 10.1002/art.23160
- PMID : 18240250
Journal ISSN0004-3591
